fluorodeoxyuridine
Floxuridine is an oncology drug that belongs to the class known as antimetabolites. Specifically, floxuridine is a pyrimidine analog, classified as a deoxyuridine. The drug is usually administered via an artery, and most often used in the treatment of colorectal cancer. The quality of life and survival rates of individuals that receive continuous hepatic artery infusion of floxuridine for colorectal cancer metastases is significantly higher than control groups. Floxuridine can also be prescribed for the treatment of kidney and stomach cancers. In vitro uses of floxuridine include 5-minute treatments of fluorouracil, floxuridine, and mitomycin to increase cell proliferation in Tenon's capsule fibroblasts. — Wikipedia
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Earliest trial started Sep 1, 1995 (NCT00001449)
Timeline
Indications
Mechanism of action
- Thymidylate kinaseINHIBITOR
DTYMK inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFloxuridine ↗
Also known as
- fluorodeoxyuridine
- fluorodeoxyuridine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02402972 | Phase 3 | Feb 1, 2015 | Baylor University, Fudan University, Harbin Medical University, Jiao Tong University, Zhejiang University |
| NCT00001449 | Phase 1 | Sep 1, 1995 | National Cancer Institute (NCI) |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Harbin Medical University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 1995 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2015 |